Principal Investigator at Al-Shifa Clinical Trial Site, Al-Shifa Trust Eye Hospital, Rawalpindi

• Sep 2023 - Present

Principal Investigator of “A Phase lll Randomized, double-Blind, Placebo-controlled study to evaluate the efficacy and safety of Bemnifosbuvir in High Risk outpatient with COVID-19” Principal Investigator of “A Phase lll Randomized, double-Blind, Placebo-controlled study to evaluate the efficacy and safety of Bemnifosbuvir in High Risk outpatient with COVID-19”

Principal Investigator at Al-Shifa Clinical Trial Site, Al-Shifa Trust Eye Hospital, Rawalpindi

• Jun 2023 - Present

Principal Investigator of “Phase lll clinical trial, Protocol Number Gates MRI-MNK01-301, titled “A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium, B. infantis) supplementation versus placebo on weight gain in underweight infants.” Principal Investigator of “Phase lll clinical trial, Protocol Number Gates MRI-MNK01-301, titled “A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium, B. infantis) supplementation versus placebo on weight gain in underweight infants.”

Member of the Senate of Health Services Academy, Islamabad

• Apr 2023 - Present

Principal Investigator at Al-Shifa Clinical Trial Site, Al-Shifa Trust Eye Hospital, Rawalpindi

• Mar 2023 - Present

Principal Investigator of “A Multi-center, Randomized, Blinded, Placebo-controlled, Phase 3 Clinical Study To Evaluate The Efficacy, Safety And Immunogenicity Of Sarscov-2 Bivalent Mrna Vaccine (Lvrna021) As Booster In Participants Aged 18 Years And Older Who Completed Primary/1 Booster Dose(s) Of Sars-cov-2 Vaccination. Principal Investigator of “A Multi-center, Randomized, Blinded, Placebo-controlled, Phase 3 Clinical Study To Evaluate The Efficacy, Safety And Immunogenicity Of Sarscov-2 Bivalent Mrna Vaccine (Lvrna021) As Booster In Participants Aged 18 Years And Older Who Completed Primary/1 Booster Dose(s) Of Sars-cov-2 Vaccination.

Principal Investigator at Al-Shifa Clinical Trial Site, Al-Shifa Trust Eye Hospital, Rawalpindi

• Nov 2022 - Present

A Randomized Double-masked, parallel-group, Multicenter Clinical Study to evaluate the Efficacy and Safety of AVT06 Compared with EU-Eylea in Subjects with Neovascular (wet) Age related Macular Degeneration (ALVOEYE). Sponsor: Alvotech Swiss AG, Al-Shifa Clinical Trial Site, Al-Shifa Trust Eye Hospital, Rawalpindi A Randomized Double-masked, parallel-group, Multicenter Clinical Study to evaluate the Efficacy and Safety of AVT06 Compared with EU-Eylea in Subjects with Neovascular (wet) Age related Macular Degeneration (ALVOEYE). Sponsor: Alvotech Swiss AG, Al-Shifa Clinical Trial Site, Al-Shifa Trust Eye Hospital, Rawalpindi

Principal Investigator at Clinical Trial Site of Al Shifa Trust Eye Hospital, Rawalpindi

• Oct 2022 - Present

Phase III Randomized Observer-blind, Multicentre Study to evaluate the Efficacy Immunogenicity and safety of Seqirus’ Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) compared to the non-Influenza vaccine when administered in healthy subjects aged 6 months through 47 months. Sponsor: CSL Seqirus, Al-Shifa Clinical Trial Site, Al-Shifa Trust Eye Hospital, Rawalpindi Phase III Randomized Observer-blind, Multicentre Study to evaluate the Efficacy Immunogenicity and safety of Seqirus’ Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) compared to the non-Influenza vaccine when administered in healthy subjects aged 6 months through 47 months. Sponsor: CSL Seqirus, Al-Shifa Clinical Trial Site, Al-Shifa Trust Eye Hospital, Rawalpindi

Professor of Public Health

• Apr 2022 - Present

Public Health Professional

• Sep 2014 - Present

Director Research

• Apr 2022 - Present

Principal Investigator at Clinical Trial Site of Al Shifa Trust Eye Hospital, Rawalpindi

• Mar 2021 - Present

An International multicentred phase III clinical trial of COVID-19 vaccine ZF2001 to determine the safety and efficacy An International multicentred phase III clinical trial of COVID-19 vaccine ZF2001 to determine the safety and efficacy

Visiting Faculty

• Jul 2016 - Present

Associate Professor

• Feb 2019 - May 2022

Research Associate

• Sep 2017 - May 2022

Principal Investigator: Validation of WHO hospital safety index tool for Emergency preparedness

• Oct 2021 - Dec 2021

Principal Investigator Sponsor: WHO EMRO, Pk. Al-Shifa Clinical Trial Site, Al-Shifa Trust Eye Hospital, Rawalpindi. Principal Investigator Sponsor: WHO EMRO, Pk. Al-Shifa Clinical Trial Site, Al-Shifa Trust Eye Hospital, Rawalpindi.

Assistant Professor

• 2014 - 2019

Fellowship Training FCPS

• Jul 2011 - Jul 2015

Senior Lecturer

• Aug 2011 - Mar 2014

Demonestrator

• Apr 2006 - Aug 2011

House Officer

• Mar 2005 - Mar 2006